Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...
Base editing biotech Beam Therapeutics is suing one of its newest rivals, alleging that the upstart company stole the secrets ...
Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...
Connect Biopharma has pointed to phase 2 data for its IL-4/IL-13 blocker as proof that the wannabe Dupixent rival can reduce ...
Highlight Therapeutics touted positive topline results in patients with localized high-risk head and neck basal cell ...
Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...
Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose. | Amgen has shed light on its ...
The Danish drugmaker is paying $300 million upfront to China’s Hengrui Pharma for a preclinical GLP-1/GIP dual receptor ...
UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...
Merck paid Daiichi $4 billion upfront in 2023 to partner on three ADCs. The FDA rejected a request for approval of one of the ...
AstraZeneca is investing $2 billion in Summit Therapeutics to accelerate the development of PD-1xVEGF bispecific ivonescimab ...
Precision Neurosciences, which specializes in brain-computer interface technology, raised $250 million in an oversubscribed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results